Credenceresearch

The   Hyperlipidemia Drugs Market   was valued at USD 15.2 billion in 2024 and is projected to reach USD 24.04 billion by 2032, expanding at a CAGR of 5.9% during the forecast period. Hyperlipidemia, characterized by abnormally elevated levels of lipids in the blood, has emerged as one of the most significant risk factors for cardiovascular diseases (CVDs)  the leading cause of mortality worldwide. The rising prevalence of obesity, sedentary lifestyles, and unhealthy dietary habits has accelerated the incidence of lipid disorders, driving strong demand for effective pharmacological interventions. The global Hyperlipidemia Drugs Market is witnessing robust growth as pharmaceutical companies, healthcare providers, and patients increasingly focus on managing cholesterol and triglyceride levels to prevent severe cardiac events such as heart attacks and strokes. Browse the full report at:  https://www.credenceresearch.com/report/hyperlipidemia-drugs-market Market Overview...

The   Americas and Europe Chagas disease drugs market   has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 6.80% between 2023 and 2030. The market was valued at USD 315.9 billion in 2022 and is expected to reach USD 500.666 billion in 2030.Chagas disease, caused by the parasite *Trypanosoma cruzi*, poses a significant health threat in Latin America and has been increasingly recognized in non-endemic regions, including parts of the United States and Europe, due to migration and travel. The market for Chagas disease drugs in the Americas and Europe has seen significant developments, driven by growing awareness, advances in medical research, and efforts to address unmet medical needs. Browse the full report at  https://www.credenceresearch.com/report/americas-and-europe-chagas-disease-drugs-market Overview of Chagas Disease Chagas disease is primarily transmitted through the bite of the triatomine bug, commonly known as the "kissing ...